Natera (NTRA)
(Delayed Data from NSDQ)
$94.04 USD
+2.38 (2.60%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $94.09 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.04 USD
+2.38 (2.60%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $94.09 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Zacks News
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -46.43% and 0.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
Enhabit (EHAB) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Enhabit (EHAB) delivered earnings and revenue surprises of -25% and 1.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 11.01% and 8.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -4.24% and 6.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HealthEquity (HQY) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
HealthEquity (HQY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Natera (NTRA) This Earnings Season?
by Zacks Equity Research
Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 82.9% in Natera (NTRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix Medical Group (MD) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -24.53% and 4.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 47% Upside in Natera (NTRA): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 47.5% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline
by Zacks Equity Research
DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Illumina (ILMN)
by Kevin Cook
Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data
Earnings Preview: Natera (NTRA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Natera (NTRA) Have the Potential to Rally 76% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 75.6% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 3.33% and 8.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Natera (NTRA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.